Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022011256 - FUSION CONSTRUCTS AND METHODS OF USING THEREOF

Publication Number WO/2022/011256
Publication Date 13.01.2022
International Application No. PCT/US2021/041082
International Filing Date 09.07.2021
IPC
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 14/71 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
71for growth factors; for growth regulators
A61K 38/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/495 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
495Transforming growth factor (TGF)
C07K 16/28 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 19/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Applicants
  • PRECIGEN, INC. [US]/[US]
Inventors
  • SABZEVARI, Helen
  • METENOU, Simon
  • CHEN, Chang Hung
  • SHAH, Rutul
Agents
  • YAO, Gene
Priority Data
63/050,39310.07.2020US
63/173,90212.04.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) FUSION CONSTRUCTS AND METHODS OF USING THEREOF
(FR) CONSTRUCTIONS DE FUSION ET LEURS MÉTHODES D'UTILISATION
Abstract
(EN) A fusion protein comprising: a first component comprising an antibody, or a fragment or variant thereof; and a second component comprising a cytokine trap or an adenosine deaminase or a fragment or variant thereof. In certain embodiments, the antibody is an anti-PD-1 antibody. In certain embodiments, the antibody binds to a tumor antigen, for example a MUC16 or MUC1 antigen. In certain embodiments, the cytokine trap is a TGF-β trap. A polynucleotide encoding such a fusion protein and a vector comprising such a polynucleotide. A composition comprising the fusion protein. A method of using the composition, including in the treatment of cancer.
(FR) L'invention concerne une protéine de fusion comprenant : un premier constituant comprenant un anticorps, ou un fragment ou un variant associé ; et un second constituant comprenant un piège à cytokine ou une adénosine désaminase ou un fragment ou un variant associé. Selon certains modes de réalisation, l'anticorps est un anticorps anti-PD-1. Selon certains modes de réalisation, l'anticorps se lie à un antigène tumoral, par exemple un antigène MUC16 ou MUC1. Selon certains modes de réalisation, le piège à cytokine est un piège à TGF-β. L'invention concerne également un polynucléotide codant pour une telle protéine de fusion et un vecteur comprenant un tel polynucléotide. L'invention concerne en outre une composition comprenant la protéine de fusion. L'invention concerne également une méthode d'utilisation de la composition, y compris dans le traitement du cancer.
Latest bibliographic data on file with the International Bureau